Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients
Chekhun, V.F.; Zhylchuk, V.E.; Lukyanova, N.Y.; Vorontsova, A.L.; Kudryavets, Y.I.
Experimental Oncology 31(2): 123-124
2009
ISSN/ISBN: 1812-9269 PMID: 19550405 Document Number: 633196
To evaluate the efficacy of the application of various chemotherapy schemes based on the immunohistochemical study of expression patterns of proteins associated with the drug resistance P-glycoprotein (P-gp), glutathione-S-transferase (GST), metallothioneins (MT) of breast cancer (BC) patients with the triple-receptor-negative (RE(-), RP(-), HER-2/neu(-)) cancer. P-gp, GST and MT expression in BC-biopsy samples from 60 BC patients was evaluated by immunohistochemical analysis. The results of the clinical observations showed that 3-years relapse-free survival rate of the patients of with P-gp, GST and MT-positive tumors treated with taxoter + adriablastin / taxoter + cyclophosphamide (TA/TC), gemcitabine + carboplatin, or TC + bevacizumab was 61.5%, 78.6% and 81.2% respectively, vs 41.2% in the control group with P-gp, GST and MT-negative tumors treated with adriablastin + cyclophosphamide (p<0.05), while overrall suvival rates were 84.4%, 92.6% and 93.8% respectively vs 70.6% in the control group (p<0.05). The study points on the possibility to elevate the efficiency of polychemotherapy by its individualization based on the expression patterns of P-gp, GST and MT on tumor cells of the patients with the triple-receptor-negative BC.